PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27965661-8	2016	Administration of adalimumab resulted in the observation of dramatically reduced tumor necrosis factor-alpha (TNFalpha) levels upon stimulation with LPS/aluminum hydroxide (>99%), with no differences between the three treatment groups in terms of magnitude or duration.	Aluminum Hydroxide	153-171	tumor necrosis factor	Homo sapiens	81-108	
27965661-8	2016	Administration of adalimumab resulted in the observation of dramatically reduced tumor necrosis factor-alpha (TNFalpha) levels upon stimulation with LPS/aluminum hydroxide (>99%), with no differences between the three treatment groups in terms of magnitude or duration.	Aluminum Hydroxide	153-171	tumor necrosis factor	Homo sapiens	110-118	
27965661-9	2016	Adalimumab also resulted in a reduction of LPS/aluminum hydroxide-induced interleukin (IL)-8 release (maximally 30%), suggested to have a causal relationship with the anti-TNFalpha treatment.	Aluminum Hydroxide	47-65	tumor necrosis factor	Homo sapiens	172-180	
10101683-10	1999	The TNF-alpha stimulated two-fold and four-fold increases in antibody levels in aqueous and Al(OH)3-based vaccine formulations, respectively.	Aluminum Hydroxide	92-99	tumor necrosis factor	Homo sapiens	4-13